*Oracea is indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients.
Oracea exerts anti-inflammatory activity and no antimicrobial effect, and should not be used to treat infections. To avoid risk of antimicrobial-related effects, including increased risk of resistance and/or side effects, do not substitute other tetracyclines for Oracea. Oracea has no bioequivalent.
Safety Considerations
In clinical trials, the most common adverse events reported were gastrointestinal upsets, nasopharyngitis/pain and nasal congestion/sinusitis. Oracea should not be used to treat microbial infections, and should be used only as indicated. This drug is contraindicated in people who have shown hypersensitivity to any of the tetracyclines, and, like other tetracycline drugs, may cause fetal harm when administered to a pregnant woman. Oracea should not be used during pregnancy, by nursing mothers or during tooth development (up to age of 8 years). Although photosensitivity was not observed in clinical trials, Oracea patients should minimize or avoid exposure to natural or artificial sunlight. All contraindications, warnings and precautions associated with tetracyclines must be considered before prescribing Oracea. The safety of Oracea treatment beyond 9 months has not been established.
Please see the full prescribing information.